Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR2 | P21802 | 2/20 | 0.46 |
| ▸ | SRC | P12931 | 7/20 | 0.45 |
| ▸ | KDR | P35968 | 3/20 | 0.43 |
| ▸ | MET | P08581 | 2/20 | 0.43 |
| ▸ | EGFR | P00533 | 2/20 | 0.43 |
| ▸ | BTK | Q06187 | 2/20 | 0.43 |
| ▸ | PLK4 | O00444 | 1/20 | 0.43 |
| ▸ | GAK | O14976 | 1/20 | 0.43 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.43 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.43 |
| ▸ | ERN1 | O75460 | 1/20 | 0.43 |
| ▸ | STK10 | O94804 | 1/20 | 0.43 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.43 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.43 |
| ▸ | ABL1 | P00519 | 1/20 | 0.43 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.43 |
| ▸ | LCK | P06239 | 1/20 | 0.43 |
| ▸ | FYN | P06241 | 1/20 | 0.43 |
| ▸ | CSF1R | P07333 | 1/20 | 0.43 |
| ▸ | YES1 | P07947 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4666490 | 0.94 | SRC (0.46) | FGFR2SRCKDRMETEGFR | |
| SCHEMBL4664603 | 0.93 | FGFR2 (0.46) | FGFR2SRCKDRMETEGFR | |
| SCHEMBL4664125 | 0.88 | SRC (0.46) | FGFR2SRCKDRMETEGFR | |
| SCHEMBL1893106 | 0.86 | LTA4H (0.50) | FGFR2SRCMETEHMT2DNMT1 | |
| SCHEMBL4666061 | 0.85 | FGFR2 (0.46) | FGFR2SRCKDRMETEGFR | |
| SCHEMBL4664535 | 0.85 | EGFR (0.41) | FGFR2SRCKDRMETEGFR | |
| SCHEMBL4666478 | 0.84 | FGFR2 (0.46) | FGFR2SRCMETEGFRBTK | |
| SCHEMBL4664564 | 0.83 | FGFR2 (0.47) | FGFR2SRCMETEHMT2DNMT1 | |
| SCHEMBL4666011 | 0.83 | KDR (0.61) | FGFR2SRCKDRMETEGFR | |
| SCHEMBL4664589 | 0.81 | PRKCQ (0.46) | FGFR2SRCKDREGFRBTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7371765-B2 | Quinoline derivatives having VEGF inhibiting activity | ASTRAZENECA AB (SE) | 2008-05-13 | — | — | US | claimed |
| US-20030199491-A1 | Quinoline derivatives having vegf inhibiting activity | ASTRAZENECA AB (SE) | 2003-10-23 | — | — | US | claimed |
| EP-1313726-A1 | QUINOLINE DERIVATIVES HAVING VEGF INHIBITING ACTIVITY | AstraZeneca AB (SE) | 2003-05-28 | — | — | EP | claimed |
| WO-2002012226-A1 | QUINOLINE DERIVATIVES HAVING VEGF INHIBITING ACTIVITY | ASTRAZENECA AB (SE) | 2002-02-14 | — | — | WO | claimed |
| US-20080312273-A1 | Quinoline Derivatives Having Vegf Inhibiting Activity | HENNEQUIN LAURENT FRANCOIS ANDRE | 2008-12-18 | — | — | US | disclosed |
| US-7371765-B2 | Quinoline derivatives having VEGF inhibiting activity | ASTRAZENECA AB (SE) | 2008-05-13 | — | — | US | disclosed |
| US-20030199491-A1 | Quinoline derivatives having vegf inhibiting activity | ASTRAZENECA AB (SE) | 2003-10-23 | — | — | US | disclosed |
| EP-1313726-A1 | QUINOLINE DERIVATIVES HAVING VEGF INHIBITING ACTIVITY | AstraZeneca AB (SE) | 2003-05-28 | — | — | EP | disclosed |
| WO-2002012226-A1 | QUINOLINE DERIVATIVES HAVING VEGF INHIBITING ACTIVITY | ASTRAZENECA AB (SE) | 2002-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312273-A1 | Quinoline Derivatives Having Vegf Inhibiting Activity | VEGFA, FLT1, FLT4 | FGFR2 544/4885SRC 1933/4885KDR 4/4885 |
| US-20030199491-A1 | Quinoline derivatives having vegf inhibiting activity | VEGFA, FLT1, FLT4 | FGFR2 575/4885SRC 3356/4885KDR 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.